NEW YORK (GenomeWeb) – Astute Medical said this week that it has received US Food and Drug Administration 510(k) clearance for its NephroCheck Test System, a protein biomarker-based test for assessing risk of acute kidney injury.
The San Diego-based company said that it plans to launch US sales of the test in coming weeks through its strategic partner Ortho Clinical Diagnostics, the exclusive sales agent for Nephrocheck.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
